Company Overview More
NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company’s pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
CEO: Javitt M.D., M.P.H., Jonathan C.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > NRXP NRX Pharmaceuticals > Detailed Quotes

NRXP NRX Pharmaceuticals

10.680+0.370+3.59%
Trading Session 10/28 13:20 ET
High
10.730
Open
10.300
Turnover
5.46M
Low
10.150
Prev.Close
10.310
Volume
520.59K
Market Cap
574.30M
P/E(TTM)
Loss
52Wk High
76.990
Shares
53.77M
P/E
Loss
52Wk Low
6.426
H Mkt Cap
213.08M
Bid-Ask Ratio
-71.43%
Historical High
76.990
H Shares
19.95M
Vol. Ratio
0.75
Historical Low
6.426
Dividend TTM
--
Div Yield TTM
--
P/B
-32.96
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.61%
Amplitude
5.63%
Avg Price
10.481
Min Trading Unit
1
Float Market Cap
213.08M
Bid-Ask Ratio
-71.43%
Historical High
76.990
Float
19.95M
Vol. Ratio
0.75
Historical Low
6.426
Dividend TTM
--
P/B
-32.96
Dividend LFY
--
Turnover Ratio
2.61%
Amplitude
5.63%
Avg Price
10.481
Min Trading Unit
1
Price Forecast

Loading...

News